Kiri Industries (KIRIINDUS): Result
Result Please find attached herewith Audited Financial Results for the quarter and year ended 31-03-2026. Please find attached herewith Audited Financial Results for the quarter and year ended 31-03-2026.
Result Please find attached herewith Audited Financial Results for the quarter and year ended 31-03-2026. Please find attached herewith Audited Financial Results for the quarter and year ended 31-03-2026.
Result Please find attached herewith Audited Financial Results for the quarter and year ended 31-03-2026. Please find attached herewith Audited Financial Results for the quarter and year ended 31-03-2026.
Company Update Pursuant to regulation 47 of the SEBI(Listing Obligation and Disclosure Requirments)Regulation, 2015. we herewith submit the copies of newspaper advertisment regarding publication of audited standalone anf consolidated financial results for the quarter and financial year ended on 31st March, 2026. Pursuant to regulation 47 of the SEBI(Listing Obligation and Disclosure Requirments)Regulation, 2015. we herewith submit the copies of newspaper advertisment regarding publication of a
Company Update Pursuant to regulation 47 of the SEBI(Listing Obligation and Disclosure Requirments)Regulation, 2015. we herewith submit the copies of newspaper advertisment regarding publication of audited standalone anf consolidated financial results for the quarter and financial year ended on 31st March, 2026. Pursuant to regulation 47 of the SEBI(Listing Obligation and Disclosure Requirments)Regulation, 2015. we herewith submit the copies of newspaper advertisment regarding publication of a
Company Update This is to inform you that there is no deviation or variation in the utilisation of IPO proceeds of the Company and therefore, we hereby submit the NIL Statement of Deviation or variation, duly reviewed and recommended by the audit committee, for the financial year ended 31-03-2026. You are requested to take this on record. This is to inform you that there is no deviation or variation in the utilisation of IPO proceeds of the Company and therefore, we hereby submit the NIL S
Company Update This is to inform you that there is no deviation or variation in the utilisation of IPO proceeds of the Company and therefore, we hereby submit the NIL Statement of Deviation or variation, duly reviewed and recommended by the audit committee, for the financial year ended 31-03-2026. You are requested to take this on record. This is to inform you that there is no deviation or variation in the utilisation of IPO proceeds of the Company and therefore, we hereby submit the NIL S
Company Update Earning Call Transcript of Analyst Meeting is attached. Earning Call Transcript of Analyst Meeting is attached.
Company Update Earning Call Transcript of Analyst Meeting is attached. Earning Call Transcript of Analyst Meeting is attached.
Company Update Pursuant to Regulation 47 of SEBI (LODR) Regulation, 2015, find the attached extract of the newspaper advertisements published for dissemination of financial results for the period ended 31st March, 2026 Pursuant to Regulation 47 of SEBI (LODR) Regulation, 2015, find the attached extract of the newspaper advertisements published for dissemination of financial results for the period ended 31st March, 2026
Company Update Pursuant to Regulation 47 of SEBI (LODR) Regulation, 2015, find the attached extract of the newspaper advertisements published for dissemination of financial results for the period ended 31st March, 2026 Pursuant to Regulation 47 of SEBI (LODR) Regulation, 2015, find the attached extract of the newspaper advertisements published for dissemination of financial results for the period ended 31st March, 2026
Outcome of Board Meeting Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Outcome of Board Meeting Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NSE & BSE filings, earnings, insider trades, and smart volume alerts — on WhatsApp or Telegram. No separate app to install.